ScPharmaceuticals Hopes To Win Payer Favor As It Prepares For Furoscix Resubmission

The company announced interim results of the FREEDOM-HF study showing nearly $18,000 in savings per heart failure patient.

heart failure illustration
scPharmaceuticals announced data from its FREEDOM-HF study of Furoscix, which it plans to resubmit to the FDA in Q4 • Source: Shutterstock

Should scPharmaceuticals, Inc.’s resubmission of Furoscix (furosemide injection) for US Food and Drug Administration approval prove successful, it will also have data to make its case to payers in the form of topline results from the FREEDOM-HF study, showing that the product was able to reduce costs related to heart failure by nearly $18,000 per patient.

The Burlington, MA-based company announced results on 13 July from FREEDOM-HF, a Phase III trial designed to provide a real-world...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.